GSK inks $1 billion cancer drug deal

Share this article:

GlaxoSmithKline said it is acquiring the rights to Synta Pharmaceuticals' skin cancer drug STA-4783 in a deal worth up to $1.1 billion.

The drug uses a new mechanism of action to kill malignant cells.

STA-4783 is administered as an injection is about to begin Phase III trials for melanoma involving 600 patients.
The companies will share costs for development in other indications and will jointly sell the drug in the US, with Synta receiving a tiered profit share, the companies said.

FDA approves generic versions of Novartis epilepsy drug

The FDA has approved the first generic versions of Novartis' epilepsy treatment Trileptal (oxcarbazepine).

Roxane Laboratories, Sun Pharmaceuticals and Glenmark Pharmaceuticals won approval to sell versions of oxcarbazepine in three strengths – 150 mg 300 mg and 600 mg.

US sales of Trileptal were $549 million in 2006.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...